AEON Biopharma, Inc.
For the period ended Dec 31, 2025. Filed Mar 30, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 30, 2026
AEON$0.16-7.4%Stored close · as of Nov 12, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. Exhibits and Financial Statement Schedules
Checking your notes…
| (1) | Financial Statements: See Item 8, “Financial Statements and Supplementary Data” for a list of financial statements. |
| (2) | Financial Statement Schedules: All schedules omitted are inapplicable or the information required is shown in the consolidated financial statements or notes thereto. |
| (3) | Exhibits Required by Item 601 of Regulation S-K: The information called for by this paragraph is set forth in Item 15(b) below. |
| (b) | Exhibits: See Exhibit Index |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.